Article Per Year (5 Year)
p-Index From 2021 - 2026
3.883
P-Index
This Author published in this journals
All Journal Pharmaciana: Jurnal Kefarmasian Jurnal Farmasi Klinik Indonesia JPSCR : Journal of Pharmaceutical Science and Clinical Research Jurnal Aplikasi dan Inovasi Iptek (JASINTEK) Jurnal Ilmiah Medicamento Poltekita: Jurnal Pengabdian Masyarakat Borneo Journal of Pharmacy
Herleeyana Meriyani
Universitas Mahasaraswati Denpasar
Agriculture, Biological Sciences & Forestry Economics, Econometrics & Finance Education Environmental Science Health Professions Medicine & Pharmacology Nursing Public Health Other

Published : 50 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 50 Documents
Search

 1   2   3   4   5 
Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review Meriyani, Herleeyana; Sanjaya, Dwi Arymbhi; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Chusna, Nurul; Ketupapa, Florentina Gabriela
Borneo Journal of Pharmacy Vol. 8 No. 1 (2025): Borneo Journal of Pharmacy
Publisher : Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33084/bjop.v8i1.7913

Abstract

Triple-negative breast cancer is an aggressive and poor prognosis subtype of breast cancer. Eribulin has shown promise in the treatment of metastatic triple-negative breast cancer (mTNBC). This review aimed to provide a specific description, evidence, and discussion of the efficacy and safety of eribulin both as monotherapy and in combination with another agent in patients with mTNBC. The search was conducted in five databases (PubMed, ScienceDirect, PLoS One, Wiley Online Library, and Cochrane Library) towards published articles during the 2013-2023 period. A total of 237 articles were identified. After removing 69 duplicates, 168 articles underwent the screening process and 10 articles met the research criteria. Eribulin monotherapy effectiveness profile includes: overall survival (10.8-17.6 months), progression-free survival (2.8-3.2 months), partial response (21.0%-58.7%), progressive disease (15.5% -47.0%), and stable disease (28.8%-32%). However, there were no cases of complete response. Combination of eribulin with other agents' effectiveness profiles includes: overall survival (8.3-14.5 months), PFS (2.6-8.1 months), partial response (31.8-76.0%), complete response (2.4-8%), progressive disease (8.0-28%), and stable disease (8.0-52.3%). Eribulin monotherapy's safety profile is similar to that of combination therapy. No grade 5 adverse event was reported during monotherapy or in combination with other agents. The grade 4 adverse events reported are neutropenia, leukopenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, vomiting, dyspnea, back pain, arthralgia, febrile neutropenia, dyspnea, constipation, general physical health deterioration, alopecia. The all-grade adverse events with a percentage above 50% are neutropenia, leukopenia, thrombocytopenia, asthenia, alopecia, elevated AST, elevated ALT, hand-foot syndrome, fatigue, anemia, peripheral neuropathy, oral mucositis, and nausea.
Cross-resistance to antibiotics of Escherichia coli in the inpatient installation of general regional hospital “X” Bali, Indonesia Mahaputra, I Putu Yudistira; Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr Asih; Siada, Nyoman Budiartha; Kamalia, Made Gek Adisti; Adrianta, Ketut Agus; Noviani, Lusy
Pharmaciana Vol. 15 No. 1 (2025): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v15i1.29209

Abstract

Escherichia coli (E. coli) is a critical-priority group of MDR bacteria and its spread can occur in hospital inpatient settings. Several studies showed that antibiotics consumption for inpatients can cause E. coli resistance to other antibiotics called cross-resistance. The aim of this study to determine the cross-resistance in E. coli to antibiotics in the inpatient installation of the regional general hospital "X" in Bali, Indonesia by analyzing the relationship between the antibiotic consumption and the percentage of antibiotic resistance of E. coli. This research is an ecological study with the independent variable is the antibiotics consumption defined as defined daily doses/100 bed-days and the dependent variable is the percentage of E. coli resistance during 2017-2020. The correlation between the level of antibiotic consumption and the percentage of E. coli resistance to antibiotics was analyzed using the Pearson correlation tests. The results showed that the consumption of tetracycline had a significant correlation with increased resistance of E. coli to meropenem and piperacillin-tazobactam (r=0.8-1.0; p<0.05). This showed that there is cross-resistance in E. coli. This incident is associated with selective pressure, horizontal and vertical gene transfer in E. coli. The consumption of tetracycline, apart from inducing the production of the tet gene which is the cause of resistance to tetracycline, can also induce the production of resistance genes to broad-spectrum beta-lactam antibiotics such as piperacillin-tazobactam and meropenem.
Efektivitas dan Efek Samping pada Terapi Multi-Drug-Resistant Tuberculosis (MDR-TB): Kajian Literatur Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Noviani, Lusy
Jurnal Ilmiah Medicamento Vol 11 No 1 (2025): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v11i1.9685

Abstract

Multi-drug-resistant tuberculosis (MDR-TB) leads to a reduced cure rate for tuberculosis treatment. The global number of MDR-TB cases remained relatively stable between 2015 and 2020 but increased in 2021. In 2020, the World Health Organization (WHO) estimated 437,000 MDR-TB cases worldwide, which rose to 450,000 cases in 2021. Various treatment regimens recommended by the WHO require a review of the literature on the efficacy and side effects of drug use in MDR-TB. This review aims to provide updated information that can be used as a reference for the early identification and management of side effects. The article was a narrative review that collected and analyzed information from various international articles on databases such as PubMed, PlosOne, and ScienceDirect from January 2014 to June 2024. A total of six relevant articles were synthesized from 609 articles. The effectiveness of MDR-TB therapy with WHO-recommended drugs has shown a high cure rate (cured>50%). The incidence of side effects in MDR-TB therapy is smaller compared to the effectiveness of treatment. However, a study conducted at Wuhan Jinyintan Hospital in China from July 2019 to December 2020 showed that all study subjects experienced side effects. This included nausea and vomiting from protionamide, gatifloxacin, and ethambutol; hyperuricemia from pyrazinamide, and hyperpigmentation from clofazimine. It is recommended that a therapy regimen be selected based on culture test results, patient conditions, and drug availability in each country.
Penggunaan Antibiotik dan Resistensi Escherichia coli and Klebsiella pneumoniae: Studi Ekologikal Lima Tahun di Sebuah Rumah Sakit Umum Daerah Sanjaya, Dwi Arymbhi; Meriyani, Herleeyana; Juanita, Rr. Asih; Siada, Nyoman Budiartha; Mahaputra, Yudistira; Kamalia, Made Gek Adisti
Jurnal Ilmiah Medicamento Vol 11 No 2 (2025): Jurnal Ilmiah Medicamento
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v11i2.11156

Abstract

Antibiotic resistance is a growing global health threat, partly driven by high antibiotic consumption. The World Health Organization (WHO) has identified critical-priority bacteria, including Escherichia coli and Klebsiella pneumoniae, due to their increasing resistance to multiple antibiotics. This study aimed to evaluate the correlation between antibiotic consumption and resistance rates in Escherichia coli and Klebsiella pneumoniae. This ecological study was conducted at a Regional Hospital in Indonesia based on retrospective inpatient data from January 2019 to December 2023. The population in this study is all data on systemic antibiotic consumption based on the J01 category of the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) classification system and antibiogram from inpatient databases. Pearson and Spearman’s rank correlation analyses were performed to examine the associations between systemic antibiotic consumption levels and the percentage of Escherichia coli and Klebsiella pneumoniae resistance to other antibiotics. The most frequently used antibiotics were cefixime (305.664 DDD/100 bed-days), levofloxacin (139.552 DDD/100 bed-days), and ceftriaxone (109.805 DDD/100 bed-days). A strong and statistically significant correlation was observed between doxycycline consumption and Escherichia coli resistance to meropenem (r=0.894; p=0.041). Moreover, consumption levels of cefazolin, ceftazidime, cefepime, and ciprofloxacin were correlated with Escherichia coli resistance to ceftriaxone (p<0.05), while cefoperazone use demonstrated a very strong and statistically significant correlation with Escherichia coli resistance to ampicillin-sulbactam (r=0.952; p=0.012). Conversely, no significant correlation was found between antibiotic consumption and resistance in Klebsiella pneumoniae, suggesting that alternative factors such as intrinsic resistance mechanisms, mobile genetic elements, and environmental reservoirs may influence resistance development.
Antibiotic consumption and resistance: a 3-years ecological study for four critical groups of bacteria in a general regional hospital Sanjaya, Dwi Arymbhi; Siada, Nyoman Budiartha; Juanita, Rr Asih; Mahaputra, I Putu Yudistira; Kamalia, Made Gek Adisti; Meriyani, Herleeyana
Pharmaciana Vol. 14 No. 1 (2024): Pharmaciana
Publisher : Universitas Ahmad Dahlan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.12928/pharmaciana.v14i1.27321

Abstract

Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae are the most critical groups of multi-drug resistant (MDR) bacteria that cause a threat in hospitals. This study identified the trend of antibiotic consumption, antibiotic resistance pattern, and the relationship between antibiotic consumption and antibiotic resistance in a critical group of bacteria in a general regional hospital. This ecological study was based on retrospective data from inpatient databases in a general regional hospital over three years (2017-2019). The trend for annual antibiotic consumption over 2017-2019 was defined as defined daily doses/100 bed-days. The relationship between total antibiotic consumption and the percentage of antibiotic resistance among four isolated critical bacteria was explored in time series analysis and linear regression. The most frequently used antibiotic was ampicillin (220.33 DDD/100 bed-days), ciprofloxacin (126.86 DDD/100 bed-days), and ampicillin-sulbactam (126.34 DDD/100 bed-days). There was a significant relationship between antibiotic consumption (ampicillin, ampicillin-sulbactam, ceftazidime, gentamicin, amikacin, and ciprofloxacin) in DDD/100 bed-days and antibiotic resistance in E. coli, K. pneumoniae, and P. aeruginosa (p<0.05) but not statically significant in A. baumannii (p=0.062). The annual usage fluctuated or remained stable, with no statistically significant trends change. The relationship between antibiotic consumption and antibiotic resistance was significant in three out of four critical groups of bacteria.
Evaluasi Kesesuaian Antibiotik berdasarkan Metode Gyssens pada Peresepan Pasien Covid-19 disertai Koinfeksi Pneumonia di Rumah Sakit “X” Kota Denpasar Rr Asih Juanita; Nyoman Budiartha Siada; Dwi Arymbhi Sanjaya; Herleeyana Meriyani; Ni Putu Nadya Kirana Wulandari
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 10, No 3 (2025)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v10i3.78815

Abstract

Koinfeksi bakteri penyebab pneumonia pada individu dengan Covid-19 berpotensi memperburuk kondisi klinis serta meningkatkan risiko morbiditas dan mortalitas apabila tidak memperoleh penanganan yang adekuat.Terapi antibiotik yang diberikan harus sesuai dengan derajat keparahan pneumonia yang diukur dengan skor Pneumonia Severity Index (PSI). Ketidaktepatan terapi antibiotik dapat meningkatkan risiko terjadinya resistensi. Oleh karena itu, evaluasi penggunaan antibiotik sangat penting dilakukan untuk meminimalkan risiko ketidaktepatan terapi yang dapat menyebabkan terjadinya resistensi bakteri terhadap antibiotik. Namun, penelitian mengenai evaluasi kesesuaian antibiotik pada peresepan pasien Covid-19 disertai koinfeksi pneumonia masih terbatas. Penelitian ini dilakukan dengan tujuan untuk mengevaluasi kesesuaian antibiotik pada peresepan pasien Covid-19 disertai koinfeksi pneumonia di Rumah Sakit “X” Kota Denpasar. Penelitian dilakukan menggunakan desain cross sectional dengan pendekatan retrospektif. Data penelitian dikumpulkan dari rekam medis pasien kemudian dievaluasi secara kualitatif menggunakan metode gyssens, secara kuantitatif dengan Prescribed Daily Dose (PDD), serta hubungan kesesuaian penggunaan antibiotik dengan perbaikan derajat keparahan dianalisis secara statistik menggunakan uji Fisher. Evaluasi kesesuaian antibiotik secara kualitatif menunjukkan sebesar 87% termasuk kategori IVA (ada alternatif antibiotik yang lebih efektif), 3% kategori IIIA (penggunaan antibiotik terlalu lama), dan 10% kategori 0 (penggunaan antibiotik tepat). Hasil evaluasi secara kuantitatif menunjukkan nilai PDD yaitu cefepime (6 gram/hari); cefotaxime (4,2 gram/hari); cefuroxime, ceftazidime, cefoperazone + sulbactam (3 gram/hari); cefoperazone (2,67 gram/hari); ceftriaxone (1 gram/hari); levofloxacin (0,75 gram/hari), azithromycin (0,5 gram/hari), dan moxifloxacin (0,4 gram/hari).Kesesuaian penggunaan antibiotik tidak memiliki hubungan terhadap perbaikan derajat keparahan pasien Covid-19 disertai koinfeksi pneumonia (p = 1,000).
Evaluasi Pemberian Terapi pada Pasien Demam Berdarah Dengue di Rumah Sakit Umum Provinsi Bali Dwi Arymbhi Sanjaya; Herleeyana Meriyani; Rr Asih Juanita; Nyoman Budiartha Siada; Made Elvenia Ambara Damayanti; Lusy Noviani
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 10, No 1 (2025)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v10i1.78958

Abstract

Sekitar 50-100 juta jiwa terjangkit demam berdarah dengue (DBD) setiap tahunnya dengan jumlah kematian mencapai 20.000 hingga 40.000 juta jiwa per tahun menurut World Health Organization (WHO). Provinsi Bali menduduki peringkat ke-3 dengan Incidence Rate (IR) DBD tertinggi pada tahun 2021 yaitu 59,8 per 100.000 penduduk. Penyakit DBD biasanya disertai dengan komplikasi dan penyakit penyerta yang dapat mengakibatkan peningkatan morbiditas dan mortalitas. Penelitian ini bertujuan mengetahui gambaran perbaikan klinis yang diamati dari parameter hematologi (leukosit, hemoglobin, hematokrit, dan trombosit) pada pasien DBD dengan komplikasi dan penyakit penyerta. Penelitian ini merupakan penelitian observasional dengan pendekatan cross-sectional yang dilakukan di rumah sakit umum Provinsi Bali. Pengambilan data dilakukan secara retrospektif yaitu data yang diperoleh dari bulan Januari 2020 hingga Desember 2021. Lima puluh tiga sampel pada penelitian diambil menggunakan teknik total sampling. Efektivitas penatalaksanaan DBD dengan komplikasi dan penyakit penyerta pada hari pertama, hari ketiga, dan hari kelima dianalisis menggunakan uji Cochran dengan post-hoc McNemar. Pasien DBD dengan komplikasi dan penyakit penyerta pada penelitian ini sejumlah 53 orang dengan 66% laki-laki dan 34% perempuan dengan rata-rata lama rawat inap yaitu 6,0 hari. Ringer laktat dan parasetamol merupakan jenis terapi yang paling banyak digunakan dalam penatalaksanaan DBD. Penatalaksanaan pasien DBD dengan komplikasi dan penyakit penyerta di rumah sakit umum Provinsi Bali pada tahun 2020-2021 menunjukan peningkatan trombosit dan leukosit yang signifikan sejak hari ketiga hingga hari kelima (p&lt;0,05). 
Kajian Literatur: Study Design Dalam Farmakoepidemiologi Untuk Mengetahui Resistensi Bakteri Terhadap Antibiotik Herleeyana Meriyani; Dwi Arymbhi Sanjaya; Rr Asih Juanita; Nyoman Budiartha Siada
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 8, No 1 (2023)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v8i1.61651

Abstract

Penelitian terkait resistensi bakteri terhadap antibiotik dapat dilakukan dengan berbagai study design. Study design merupakan salah satu titik kritis dalam penelitian resistensi bakteri terhadap antibiotik. Penelitian ini bertujuan untuk memberikan gambaran kelebihan dan kekurangan dari study design yang digunakan dalam penelitian farmakoepidemiologi tentang resistensi bakteri terhadap antibiotik. Pencarian literatur dilakukan secara elektronik untuk artikel yang dipublikasikan tahun 2011 hingga 30 Juni 2021 pada basis data EBSCO, Plos One, Proquest, PubMed, ScienceDirect, dan Google Scholar. Kriteria inklusi meliputi original article dengan desain cohort (prospective dan retrospective), case control, cross-sectional dan ecological study; memiliki Digital Object Identifier (DOI); dipublikasi 10 tahun terakhir; serta mengunakan Bahasa Inggris. Artikel dalam bentuk review, tidak merupakan full text, dan artikel dengan jumlah sampel penelitian yang tidak jelas tidak disertakan dalam kajian ini. Artikel yang terkumpul dari 6 database sejumlah 209 artikel (EBSCO 45 artikel, Plos One 42 artikel, ProQuest 32 artikel, PubMed 68 artikel, ScienceDirect 19 artikel dan Google Scholar 3 artikel). Duplikasi artikel dieksklusi (29 artikel). Artikel tidak memenuhi kriteria inklusi (86 artikel), 64 artikel tidak relavan dengan tujuan penelitian, sehingga diperoleh 30 artikel dalam studi ini. Rancangan penelitian pada penelitian ini yaitu case-control (2 artikel), cohort-prospective (14 artikel), cohort-retrospective (5 artikel), cross-sectional (8 artikel) dan ecological study (1 artikel). Masing-masing rancangan memiliki kelebihan dan kekurangannya masing-masing. Pemilihan desain studi dalam penelitian resistensi bakteri terhadap antibiotik dilakukan sesuai dengan tujuan penelitian, jenis paparan yang diamati, jenis outcome serta tipe penelitian (comparative, correlative study) serta ketersediaan sumber daya dalam melakukan penelitian resistensi bakteri terhadap antibiotik.
Evaluasi Rasionalitas Pengobatan Pasien Dengue Hemorrhagic Fever dengan Komplikasi dan Komorbiditas di Rumah Sakit “X” Provinsi Bali Rr Asih Juanita; Herleeyana Meriyani; Dwi Arymbhi Sanjaya; Nyoman Budiartha Siada; Nyoman Ayu Prascitasari
JPSCR: Journal of Pharmaceutical Science and Clinical Research Vol 10, No 2 (2025)
Publisher : Universitas Sebelas Maret

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20961/jpscr.v10i2.92941

Abstract

Penggunaan obat pada pasien Dengue Hemorrhagic Fever (DHF) dengan komplikasi dan komorbiditas perlu mendapat perhatian khusus untuk menghindari kejadian Drug Related Problems (DRPs) yang dapat memengaruhi luaran klinis. Penelitian ini bertujuan untuk mengevaluasi rasionalitas pengobatan pada pasien DHF dengan komplikasi dan komorbiditas di Rumah Sakit “X” Provinsi Bali. Jenis penelitian yang digunakan adalah observasional dengan rancangan cross-sectional. Data rekam medis pasien dikumpulkan secara retrospektif tahun 2020-2021. Penilaian rasionalitas pengobatan dilakukan dengan analisis DRPs menggunakan instrumen Pharmaceutical Care Network Europe Association (PCNE) versi 9.1. Luaran klinis dianalisis berdasarkan nilai trombosit, hematokrit, leukosit, dan hemoglobin. Analisis hubungan rasionalitas pengobatan terhadap luaran klinis dilakukan menggunakan uji Chi-square. Dari total 115 pasien yang memenuhi kriteria penelitian, terjadi DRPs pada 33% pasien dan 67% tidak terjadi DRPs. DRPs yang terjadi yaitu P3.2 Unclear problem/complaint (51%); P1.2 Effect of drug treatment not optimal (28%); P1.3 Untreated symptoms or indication (13%); serta P3.1 Unnecessary drug-treatment (8%). Rasionalitas pengobatan tidak berhubungan dengan luaran klinis pasien DHF dengan komplikasi dan komorbiditas di Rumah Sakit “X” Provinsi Bali (p&gt;0,05).
The Association between Resistance of Sepsis-Inducing Bacteria to First-Line Antibiotics and Sepsis Outcome: A Retrospective Cross-Sectional Study Herleeyana Meriyani; Dwi Arymbhi Sanjaya; Rr. Asih Juanita; Nyoman Budiartha Siada; I Wayan Maysa Yudiartha; Kadek Suryawan
Jurnal Ilmiah Medicamento Vol 12 No 1 (2026): Jurnal Ilmiah Medicamento (In progress)
Publisher : Fakultas Farmasi Universitas Mahasaraswati Denpasar

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36733/medicamento.v12i1.13597

Abstract

Background: Sepsis is a significant infectious disease linked to high mortality rates. Several bacterial pathogens that cause sepsis have shown resistance to first-line antibiotics. This resistance in sepsis-causing bacteria to initial antibiotic agents threatens treatment success, elevating mortality risk, healthcare costs, and prolonged hospital stays.Objective: This study aimed to investigate the relationship between the resistance of sepsis-causing bacteria to first-line antibiotics and sepsis treatment outcomes.Methods: This cross-sectional study was a single-center retrospective study. Data were collected from sepsis patients admitted to the intensive care unit of a general hospital in Bali between 2022 and 2023. The patients included in this study were those with a positive bacterial infection, as provided in the culture result. Therapy outcomes were evaluated based on discharge status: improved or unimproved (deceased). The resistance of sepsis-causing bacteria to first-line antibiotics, including fluoroquinolones, third- and fourth-generation cephalosporins, piperacillin-tazobactam, and vancomycin, was assessed through blood cultures. The relationship between antibiotic resistance and therapy outcomes was analyzed using the Gamma correlation coefficient. This study included 57 of 108 sepsis patients, primarily male (57.89%) and older than 60 years (57.89%).Results: A strong, significant positive correlation was observed between the resistance of sepsis-causing bacteria to third-generation cephalosporins and therapy outcomes (p=0.001; r=0.637). In contrast, resistance to fluoroquinolones (p=0.108; r=0.387), fourth-generation cephalosporins (p=0.377; r=-0.199), piperacillin-tazobactam (p=0.816; r=-0.060), and vancomycin (p=0.911; r=0.030) did not significantly impact therapy outcomes. The outcome of sepsis therapy is associated with resistance of sepsis-causing bacteria to third-generation cephalosporins but not to fluoroquinolones, fourth-generation cephalosporins, piperacillin-tazobactam, or vancomycin. This study uses a relatively small sample size, which precludes subgroup analyses.Conclusion: Non-significant findings for some antibiotics may reflect insufficient power; further study is needed to assess the correlation between resistance of sepsis-causing bacteria to fluoroquinolones, fourth-generation cephalosporins, piperacillin-tazobactam, and vancomycin.
Co-Authors Ciptawati, Ni Wayan Dwi A. Sanjaya Dwi Arymbhi Sanjaya Dwi Arymbhi Sanjaya Dwi Arymbhi Sanjaya Dwi Arymbhi Sanjaya Dwi Arymbhi Sanjaya Dwi Arymbhi Sanjaya Dwi Arymbhi Sanjaya Fitria Megawati Fitria Megawati Fitria Megawati Fredinan Yulianda I Made Agus Sunadi Putra I Made Agus Sunadi Putra I Putu Yudistira Mahaputra I Wayan Maysa Yudiartha Kadek Suryawan Kamalia, Made Gek Adisti Ketupapa, Florentina Gabriela Ketut Agus Adrianta Komang Triani Lestari Lusy Noviani Made Elvenia Ambara Damayanti Made Gek Adisti Kamalia Mahaputra, I Putu Yudistira Mahaputra, Yudistira Megawati, Fitria Ni Kadek Ayu Sartikawati Ni Kadek Sukertiasih Ni Made Dharma Shantini Suena Ni Nyoman Wahyu Udayani Ni Putu Nadya Kirana Wulandari Ni Putu Udayana Antari Ni Wayan Ciptawati Ni Wayan Sutariani Nurul Chusna Nyoman Ayu Prascitasari Nyoman B. Siada Nyoman Budiartha Siada Nyoman Budiartha Siada Nyoman Budiartha Siada Nyoman Budiartha Siada Nyoman Budiartha Siada Nyoman Budiartha Siada Nyoman Budiartha Siada Putra, I Made Agus Sunadi Putu Sukma Purnamasari Rr Asih Juanita Rr Asih Juanita Rr Asih Juanita RR. Asih Juanita Rr. Asih Juanita SARTIKAWATI, NI KADEK AYU Siluh Putu Astini Triska Ananda Rahayu Wardani, I Gusti Agung Ayu Kusuma Wintariani, Ni Putu Woro Enjang Santi Prihatin